A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2016
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 15 Mar 2015 Results presented at the American College of Cardiology (ACC) Annual Scientific Session 2015, according to Alnylam Pharmaceuticals media release.
- 15 Mar 2015 Results published in the Media Release.
- 25 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History